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Abstract
The identification of key tumorigenic events in Sonic Hedgehog subgroup medulloblastomas 
(MBSHH) will be essential for the development of individualized therapies and improved 
outcomes. However, beyond confirmation of characteristic SHH-pathway mutations, recent 
genome-wide sequencing studies have not revealed commonly-mutated genes with widespread 
relevance as potential therapeutic targets. We therefore examined any role for epigenetic DNA 
methylation events in MBSHH using a cross-species approach to candidate identification, 
prioritization and validation. MBSHH–associated DNA methylation events were first identified in 
216 subgrouped human medulloblastomas (50 MBSHH, 28 WNT, 44 Group 3, 94 Group 4) and 
their conservation then assessed in tumors arising from four independent murine models of Shh 
medulloblastoma, alongside any role in tumorigenesis using functional assessments in mouse and 
human models. This strategy identified widespread regional CpG hypo-methylation of VAV1, 
leading to its elevated expression, as a conserved aberrant epigenetic event which characterizes the 
majority of MBSHH tumors in both species, and is associated with a poor outcome in MBSHH 
patients. Moreover, direct modulation of VAV1 in mouse and human models revealed a critical 
role in tumor maintenance, and its abrogation markedly reduced medulloblastoma growth. Further, 
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Vav1 activity regulated granule neuron precursor (GNP) germinal zone exit and migration 
initiation in an ex vivo model of early post-natal cerebellar development. These findings establish 
VAV1 as a critical epigenetically-regulated oncogene with a key role in MBSHH maintenance, and 
highlight its potential as a validated therapeutic target and prognostic biomarker for the improved 
therapy of medulloblastoma.
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Introduction
Medulloblastoma, the most common malignant brain tumor of childhood, comprises four 
consensus molecular subtypes [Wnt/Wingless (WNT), Sonic Hedgehog (SHH), Group 3 and 
Group 4] characterized by distinct clinical, molecular and pathological features, and by 
different postulated cells of origin.1-4 These advances are rapidly informing targeted 
therapeutic strategies and the design of individualized clinical trials aimed at increased cure 
rates and reduced long-term treatment side-effects.5
Targeted therapies for MBSHH (~25% of patients) are currently most advanced. MBSHH 
(~70% five-year survival) peak in infancy, but also occur throughout childhood and into 
adulthood.2 Tumors are characterized by SHH signaling activation via mechanisms 
including pathway mutations (PTCH1 (~45% of MBSHH), SUFU (~8%) and SMO (~14%)) 
and gene amplifications (GLI2 (~8%), MYCN (~13%)).6 Early clinical trials of SHH 
pathway inhibitors (targeting SMO) show promise,7, 8 but significant challenges are 
predicted in their application, with reported developmental toxicities, 9 acquired drug 
resistance, 10 and intrinsic insensitivity in tumors with pathway activation downstream of 
SMO (e.g. SUFU mutation, GLI2 and MYCN amplification).6 Thus, there is clear need to 
identify additional targetable genes and pathways in MBSHH, to support additional or 
alternative targeted therapeutic strategies.
The identification of therapeutically exploitable ‘driver’ events from the many aberrations 
identified in contemporary genome-wide genetic and epigenetic investigations represents a 
major challenge. Recent genome-wide mutational screens in MBSHH have revealed notable 
genetic diversity, however the most frequent novel coding mutations characterize small 
patient groups (e.g. MLL2 (~16% of MBSHH) and DDX3X (~26%)) and most mutations are 
found singly in individual tumors.6, 11 Significantly, a prominent role for epigenetic 
alterations is also emerging.6, 12-14 Our recent DNA methylation profiling study of 230 
medulloblastomas showed MBSHH harbor specific DNA methylation events which 
characterize significant proportions of tumors and identify candidate disease driver genes.15 
However, their functional relevance and contribution to tumor development is unknown.
Genetically-engineered mouse models, which give rise to medulloblastoma with constitutive 
SHH pathway activation, support granule neuron precursors (GNPs) of the developing 
cerebellum as their cells of origin4, 16-19 and provide opportunities to systematically 
interrogate epigenetic events in the mouse medulloblastoma genome. It may be reasoned 
Lindsey et al. Page 2
Oncogene. Author manuscript; available in PMC 2016 March 03.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
that any conservation of aberrant DNA methylation events between MBSHH and SHH-
driven mouse medulloblastomas could identify events important in tumorigenesis and 
provide faithful model systems for their functional investigation.
Here we report a cross-species investigation of DNA methylation events in 
medulloblastomas from 230 human patients (216 with subgroup assigned (50 MBSHH, 28 
WNT
,
 44 Group 3, 94 Group 4)) and four independent SHH mouse models. Using this 
approach, we identify regional hypo-methylation of VAV1, leading to its elevated 
expression, as a conserved and widespread epigenetic event in both species, affecting the 
majority of MBSHH tumors. We further show (i) VAV1 status predicts poor treatment 
outcome within the MBSHH subgroup and (ii) VAV1 plays a critical functional role in 
medulloblastoma maintenance, highlighting its clear potential as a biomarker and validated 
drug target in MBSHH. Finally, we provide evidence that Vav1 is expressed in early 
cerebellar GNPs, where its activity regulates their development. The roles characterized for 
VAV1 in MBSHH, and in cerebellar development, demonstrate the potential of comparative 
tumor epigenomics using genetically-engineered mice to identify, prioritize and functionally 
analyze critical molecular events in human tumorigenesis.
Results
Human MBSHH tumors harbor distinct and characteristic DNA methylation events
We first sought to identify DNA methylation events which may contribute to human 
MBSHH. We have previously shown the four major medulloblastoma molecular disease 
subgroups -WNT, SHH, Group3 and Group 4 - may be distinguished based on their DNA 
methylation patterns (Supplementary Figure S1A).15 Comparison of tumor DNA 
methylation patterns of subgrouped medulloblastomas (n=216) with the normal cerebellum 
(n=21) showed normal cerebella form a distinct group, which is most closely related to 
MBSHH (Supplementary Figure S1B).
Statistical analysis identified 15 genes (associated with 18 CpG sites) whose methylation 
status significantly distinguished MBSHH from other medulloblastomas, and from the 
normal cerebellum (Figure 1A). Both hypo- (n=6) and hyper-methylation (n=9) events were 
observed. In addition, the methylation status of RASSF1A and COL1A2 CpG sites, two of 
the most frequent hyper-methylation events reported in medulloblastoma,12, 20 was assessed 
and showed expected frequent and tumor-specific methylation which affected all tumor 
subgroups (Figure 1A). In summary, these investigations show MBSHH harbor distinct DNA 
methylation patterns and identify a series of gene-specific DNA methylation events for 
further analysis.
Identification of conserved DNA methylation events in mouse models of SHH-driven 
medulloblastoma
We next assessed the DNA methylation status of regions orthologous to those encompassing 
the CpG sites identified in human MBSHH tumors, in medulloblastomas from four 
independent SHH-associated mouse models, alongside strain-matched normal cerebella of 
different developmental stages. Eight orthologous regions surrounding CpG sites which 
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showed MBSHH-specific methylation, alongside regions surrounding RASSF1A and 
COL1A2, were selected for analysis by direct bisulfite sequencing (Figure1, Supplementary 
Table S1 and Figure S2A, B). The overall cerebellar methylation status was conserved in the 
majority of regions assessed (7/10; Figure 1C); cerebella from different mouse strains, 
including immature and mature mice, showed equivalent patterns (Figure 1B). Consistent 
methylation profiles were also observed across tumors from the different SHH-associated 
mouse models (Figure 1B).
Most strikingly, VAV1 showed widespread tumor-specific patterns of hypo-methylation 
across the regions examined which were of equivalent extent, magnitude and frequency in 
human MBSHH and SHH mouse tumor models, compared to cerebellar controls. In all 
mouse tumors, the majority of CpG sites across the Vav1 region were hypo-methylated 
(Figure 1B, C; Supplementary Figure S2C), while in humans, VAV1 hypo-methylation 
encompassed all assessed CpG sites (Supplementary Figures S2B and S3A, B, C). Tal1, 
Dsc2, Spdef and Rassf1a also showed statistically significant methylation differences, but 
these represented methylation changes in individual samples or CpG sites and were not 
comparable to differences seen between human MBSHH tumors and cerebella (Figure 1B, 
C). These findings identify regional VAV1 hypo-methylation as a frequent evolutionarily 
conserved epigenetic event in human MBSHH, for further analysis.
VAV1 hypo-methylation characterizes the majority of MBSHH and is associated with a poor 
outcome
VAV1 hypo-methylation was a frequent region-wide event in human MBSHH (70% (36/50)), 
affecting only occasional tumors (2% (4/166)) within the other molecular subgroups (Figure 
2A, B; Supplementary Figure S3C). In whole-cohort analysis (n=230), VAV1 hypo-
methylation was significantly correlated with desmoplastic nodular (DN) pathology 
(p=2.3×10−11, Fisher’s exact test), infant patients (<3 years at diagnosis; p=0.003)) and 
MYCN gene amplification (p=0.02) (Figure 2C), consistent with the established associations 
of these features with MBSHH in this cohort 15.
Within the MBSHH subgroup, VAV1 hypo-methylation was observed across tumors of all 
key clinical, pathological and molecular demographics, and did not associate with any 
particular medulloblastoma disease feature; it is however notable that all MYCN 
amplifications occurred in VAV1 hypo-methylated tumors (Figure 2C). Associations were 
assessed using the CpG site recognized by the VAV1_e9 probe which lies within the region 
conserved between humans and mice. Notably, VAV1 hypo-methylation was associated with 
a poor outcome amongst MBSHH tumors (Figure 2D), in an analysis of 36 patients aged ≥3 
years at diagnosis, who received standard upfront radiotherapy and chemotherapy and were 
derived predominantly from the PNET3 clinical trial.15, 21 The rarity of VAV1 hypo-
methylation in non-MBSHH precluded the analysis of any relationships to survival in these 
subgroups. Thus, VAV1 hypo-methylation occurs frequently within the MBSHH subgroup 
and is associated with specific disease features and poor outcomes.
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VAV1 hypo-methylation is associated with elevated expression in human and mouse SHH 
medulloblastomas
VAV1 showed a direct methylation-dependent relationship between methylation status and 
expression in human medulloblastoma cell lines treated with the DNA methyltransferase 
inhibitor, 5′-Aza-2′-deoxycytidine (5-azaCdR) (Figure 3A, B). All VAV1-methylated cell 
lines (D283Med, MEB-Med8a and D425Med) had low VAV1 expression which was 
upregulated following 5-azaCdR de-methylation. In contrast, VAV1 expression was higher in 
hypo-methylated cells (DAOY) and was unaffected by 5-azaCdR. Consistent with this, Vav1 
expression was significantly increased in mouse tumors (all hypo-methylated) compared to 
normal adult cerebella (all methylated) (Figure 3C; Supplementary Figure S2C), and in 
VAV1 hypo-methylated human tumors compared to VAV1 methylated tumors or the normal 
human cerebellum (all methylated) (Figure 3D). Finally, VAV1 expression was highest in 
MBSHH tumors (associated with VAV1 hypo-methylation) compared to the other 
medulloblastoma molecular subgroups (Figure 3E; data from published dataset22). These 
demonstrated relationships between VAV1 methylation and expression are consistent with 
the hypo-methylation-dependent elevation of VAV1 expression in human and mouse SHH-
subgroup medulloblastomas.
VAV1 expression is pro-proliferative in human medulloblastoma cells
To investigate the functional consequences of VAV1 hypo-methylation and expression in 
human medulloblastoma, we modelled the effect of silencing VAV1 over-expression in 
hypo-methylated human medulloblastoma cells. VAV1 silencing using siRNA (60-80% 
knockdown, day 3; Figure 4A, B) significantly decreased proliferation (Figure 4C) and 
altered cell cycle distribution; a pronounced G2 arrest and increased G0/sub-G1 fraction 
occurred following VAV1 knockdown (Figure 4D). These data support a pro-proliferative 
role for the elevated VAV1 expression observed in VAV1 hypo-methylated human 
medulloblastoma cells.
Dominant-negative Vav1 suppresses medulloblastoma maintenance in the Ptch1+/− 
Cdkn2c−/− mouse model
To address whether Vav1 was required for tumor growth in a mouse SHH medulloblastoma 
model, we purified tumor cells from spontaneously occurring Vav1 hypomethylated/
overexpressing medulloblastomas arising in Ptch1+/− Cdkn2c−/− mice (Figures 1,3C, 
Supplementary Figure S2C) and infected them with retroviruses carrying GFP alone, wild-
type Vav1/GFP or a dominant-negative form of Vav1 (Vav1DN/GFP 23, 24), an isolated 
amino terminal fragment (residues 1-186), which acts in trans to inhibit the GEF function of 
native Vav1. Cells from each infected pool were transplanted in the flanks of recipient nude 
mice and tumor formation assessed.
Approximately two months post-implantation, tumors appeared on the flanks of all mice 
transplanted with tumor cells marked with GFP only or with Vav1/GFP viruses. These 
tumors harbored similar weights (Figure 5C). In contrast, tumors that developed after the 
transplant of tumor cells infected with Vav1DN-carrying viruses were smaller than those 
derived from GFP only-infected cells and only 6 out of 9 transplants induced secondary 
tumors (Figure 5A-C). Thus, enforced expression of a Vav1 dominant-negative mutant 
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inhibits tumor maintenance in our model. Ectopic over-expression of wild-type Vav1 did not 
impact, suggesting interference with the endogenous Vav1 expression associated with its 
hypo-methylation is important for the inhibition of tumor growth.
To examine the contribution of retrovirally-infected cells to tumor development, we 
analyzed by FACS the percentage of infected GFP-positive tumor cells before transplant and 
in each secondary tumor. On average, we found a ~40% reduction of Vav1DN-infected 
GFP+ cells in secondary tumors compared to the initially infected pool (Figure 5D). In 
contrast, when tumor cells were infected with GFP-only retroviruses, the percentage of GFP 
positive cells increased by ~ 20% in the secondary tumors (Figure 5D). Consistent with the 
tumor weight, enforced wild-type Vav1 expression did not affect the percentage of GFP+ 
cells in the secondary flank tumors (Figure 5D).
In contrast, enforced wild–type Vav1 expression did not appear to contribute significantly to 
medulloblastoma initiation in the Ptch1+/− Cdkn2c−/− model. Cerebellar granule neuron 
progenitors (GNPs), the cell type of origin of MBSHH, were enriched from the cerebella of 
postnatal (P) day 7, Ptch1+/− Cdkn2c−/− pups, then infected with retroviruses carrying 
GFP-alone or co-expressing wild-type Vav1. Mycn-carrying retroviruses were used as a 
positive control. 25 Average infection efficiencies were comparable (30.86% for GFP, 
35.34% for Vav1/GFP and 40.28% for Mycn/GFP). Tumors failed to develop more than 6 
months after stereotactic transplantation of GNPs, infected with GFP only containing virus 
(n=7) or co-expressing wild-type Vav1 (n=8), into the cerebral cortex. GNPs infected with a 
Mycn containing retrovirus induced medulloblastomas within 2 months as previously shown 
(n=7/725) (Figure 5E). In summary, dominant-negative Vav1 suppressed medulloblastoma 
maintenance in our Ptch1+/− Cdkn2c−/− mouse model.
Vav1 activity regulates granule neuron precursor (GNP) germinal zone exit and migration 
initiation in normal cerebellar development
We next examined whether Vav1 activity had any effect on the development of GNPs and 
postmitotic cerebellar granule neurons (CGNs). GNPs are located near the cerebellar surface 
in a germinal zone (GZ) called the external germinal layer (EGL), whereas after cell cycle 
exit and neuronal differentiation, CGNs exit their GZ by migrating away from the EGL to 
cross the molecular layer (ML) and eventually reside within the internal granule layer 
(IGL).26 GNP or CGN position with the developing cerebellar cortex thus represent an 
excellent model to examine neuronal progenitor maturation, as cells of the CGN lineage 
occupy stereotyped positions in the developing cerebellar cortex dependent upon their 
differentiation status.26 We first found Vav1 was expressed at elevated levels in developing 
(P7) GNPs compared to cerebella from wild-type mice (Figure 6A). Then, we used 
electroporation of early post-natal mouse cerebellum followed by ex vivo culture of 
organotypic cerebellar slices as an assay to examine GNP germinal zone (GZ) exit and 
migration initiation.27 Expression constructs for Vav1DN and the fluorescent nuclear 
reporter H2B-mCherry were co-electroporated into the cerebellar cortices of P7 mice and 
cerebellar slices were cultured ex vivo. While control GNPs remained within the EGL after 
24 hours, cells expressing elevated Vav1DN entered the ML and IGL (Figure 6B, D), 
suggesting that inhibition of Vav1 activity is sufficient to induce precocious GZ exit.
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Given that Vav1 inhibition appeared to regulate GNP GZ exit and migration initiation, we 
next evaluated whether Vav1 activity could regulate GNP’s GZ exit using a gain-of-function 
approach. Expression vectors for a constitutively active Vav1 lacking the auto-inhibitory 
amino terminal domain (Vav1CA28 ) were electroporated into P7 EGL. After 2 days of ex 
vivo culture, control CGNs initiated migration correctly and had entered the molecular layer 
and IGL while Vav1CA expressing CGNs remained within the EGL (Figure 6C, E), 
suggesting that activation of Vav-1 activity blocks GZ exit. Finally, we examined the 
morphology of Vav1DN and Vav1CA over expressing cells via time-lapse microscopy of in 
vitro CGN cultures. Whilst control neurons and Vav1DN expressing neurons elaborated the 
long neurites of mature CGNs, Vav1CA expressing retained the short processes which are 
the characteristic of immature CGNs (See Supplementary Movies 1-3).
Together, these data show Vav1 activity blocks GNP exit from the developing cerebellar 
germinal zone and indicate a role in normal cerebellar development.
Discussion
Our investigations of DNA methylation events in human MBSHH and four independent SHH 
mouse medulloblastoma models have identified VAV1 hypo-methylation as a conserved and 
defining MBSHH event which affects around 70% of human tumors, more common than any 
mutated gene (PTCH1 (~45%) and TERT (~30%) are most frequent),6, 29, 30 and which 
describes MBSHH of all key clinical, pathological and molecular demographics. Its complete 
regional de-methylation (Supplementary Figure S3), coupled with an absence of significant 
copy number alterations or mutations in large cohorts [data from11, 22] indicates 
hypomethylation is its major mechanism of alteration. VAV1 methylation status is intimately 
related to its expression; VAV1 expression is controlled by methylation in human cell lines 
and its hypo-methylation, in both mouse and human tumors, is significantly associated with 
increased expression. Consistent with this, the region of uniform hypo-methylation we have 
characterized overlaps with the minimal region shown in mutagenesis studies to be 
sufficient to drive VAV1 expression.31
Modelling VAV1 epigenetic silencing in mouse and human tumor models validated a role 
for VAV1 expression in SHH-associated tumor growth and maintenance. Introduction of 
dominant-negative Vav1 into tumor cells from established hypo-methylated Ptch1+/− 
Cdkn2c−/− mouse tumors significantly reduced tumor re-establishment and growth. In 
contrast, enforced expression of wild-type Vav1 did not further increase tumorigenic 
potential, indicating endogenous Vav1 levels in hypo-methylated cells are sufficient to 
promote tumorigenesis. Further, the impact of VAV1 silencing on proliferation and cell 
cycle arrest in VAV1 hypo-methylated human cells is consistent with VAV1-dependent 
effects in other cancer cell types, 24, 32 while the identification of Vav1 mutation as a SHH-
cooperating event in a murine insertional mutagenesis screen 33 provides further genetic 
evidence to substantiate its role in MBSHH. Any role for VAV1 in tumor initiation is less 
clear; enforced Vav1 expression in engrafted Ptch1+/− Cdkn2c−/− GNPs did not cause tumor 
development, in contrast to Mycn controls. 25 However, given Ptch1’s established role in 
initiation, 34 these results do not preclude Vav1 involvement. Future strategies to examine 
Lindsey et al. Page 7
Oncogene. Author manuscript; available in PMC 2016 March 03.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
any interaction between Ptch1 and Vav1 in spontaneous SHH-tumor formation, which 
account for endogenous Vav1 expression35 should prove informative.
The role of VAV1 in the majority of MBSHH tumors, together with the inhibition of tumor 
growth following its silencing, identify and validate VAV1 and its dependent pathways as 
important potential therapeutic targets. In particular, its homogeneous mechanism of 
activation and SHH-independence highlight potential applications for alternative or second-
line / combination therapies with SHH pathway inhibitors. Consistent with its 
protumorigenic role, VAV1 hypo-methylation was associated with a poor outcome in clinical 
trial-derived MBSHH patients,15, 21 supporting its utility as both a prognostic and predictive 
biomarker for use in stratified therapies. Multivariate survival analysis, validation in 
alternative cohorts, and investigations in all disease demographic groups, are now essential 
to confirm reproducibility of these initial findings prior to any clinical application.
Vav1 is expressed in GNPs [the proposed cells of origin for MBSHH36] during early 
cerebellar development. Our data show its activity blocks GNP exit from the developing 
cerebellar germinal zone, suggesting a mechanism by which disruption of these processes by 
Vav1 hypo-methylation and expression may contribute to medulloblastoma tumorigenesis. 
These findings further emphasize the intimate links between cerebellar development and 
medulloblastoma, and evidence that temporally/spatially restricted pathways in normal 
cerebellar development become constitutively activated during tumorigenesis.36 Coupled 
with the established roles of SHH pathway activation in GNP proliferation 34 and MBSHH, 
our data also suggest common functions for Vav1 and SHH in both processes, and provide a 
basis for the investigation of any functional interaction. Interestingly, Vav3 plays roles in the 
migration of GNPs from the EGL to the IGL, and in the survival of GCNs in the IGL37, 
implicating the involvement of multiple Vav family members in cerebellar development. 
Consideration of developmental toxicities will thus be essential in developing targeted 
therapies against VAV1, however that Vav1−/− mice are viable and healthy apart from 
impaired T-cell development 38 is encouraging.
How might VAV1 exert its function? VAV1 expression is normally confined to the 
hematopoietic system, where its best characterized function is as a GDP/GTP nucleotide 
exchange factor for the Rho/Rac family of GTPases. However, roles in multiple diverse 
processes including activation of the JNK, ERK, Ras, NF-kB, and NFAT pathways, 
cytoskeleton organization, migration and TP53-mediated apoptosis have also been 
described.32, 39, 40 Direct small molecule VAV1 inhibitors are not widely reported, however 
strategies against many of its candidate downstream pathways are in development.41 A 
detailed exploration of the pathways impacted by VAV1 in MBSHH and normal cerebellar 
development will therefore now be essential to understand their mechanistic basis and to 
enable therapeutic targeting.
Finally, available evidence suggests an emerging widespread relevance for VAV1 in tumor 
development. In addition to its expression in hematopoiesis and hematological 
malignancies,42 VAV1 expression has been reported in solid tumors including 
neuroblastomas32 and pancreatic ductal adenocarcinomas, where expression was associated 
with a poor survival outcome, and with demethylation of the VAV1 promoter in tumor cell 
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lines. 24 In preliminary investigations of other pediatric brain tumor types, VAV1 hypo-
methylation at the CpG residues involved in MBSHH is also a feature of a proportion of 
posterior fossa ependymomas, high-grade gliomas and CNS-PNETs, as well as occasional 
non-MBSHH medulloblastomas (Supplementary Figure S4; Figure 2), suggesting potential 
roles in their development for further investigation.
Materials and Methods
Patient samples, DNA methylation profiling and subgroup status
DNA methylation profiling and consensus clustering of molecular subgroups was performed 
as previously described15 on 230 primary medulloblastomas (of which 216 were confidently 
assigned to a subgroup), alongside 21 normal non-neoplastic cerebella (representing fetal, 
infant and adult samples43), using the Illumina GoldenGate Cancer Panel I microarray. 44 
The DNA methylation status of 1505 CpG sites (807 genes) was represented as a β-score 
from zero (unmethylated) to one (methylated). Subgroup status was additionally assessed 
using mRNA signature,45 immunohistochemistry (IHC) 46 and mutational (CTNNB1) 45 
biomarker assays.
5-azaCdR treatment of human cell lines
Four human medulloblastoma cell lines (D283Med, MEB-Med8a, D425Med and DAOY) 
were grown in the presence or absence of the demethylating agent 5-azaCdR as previously 
described.12 Cell lines were validated by confirmation of published karyotypes. 47
Mouse tumor and tissue samples
Mouse medulloblastomas from Smo/Smo mice 18, Ptch1+/− Cdkn2c−/− mice 16, Cdkn2c−/− 
p53FL/−, Nestin-Cre+ mice irradiated at P7 16 and Sufu+/− p53 −/− mice 17 (all n=3) were 
assessed alongside control cerebella from strain-matched non-transgenic mice.
Percoll-enriched GNPs from post-natal P7 cerebellum and GNP-like tumor cells from 
spontaneously-arisen medulloblastomas were purified from Ptch1+/− Cdkn2c−/− mice. 16 P7 
cerebellar GNPs were also purified from wild-type mice. CD-1 nu/nu mice (Charles River 
Laboratories, Wilmington, MA) were used for cortical or flank transplantation. Wild type 
C57BL/6 mice (Charles River Laboratories, Wilmington, MA) were used for ex vivo 
cerebellar slice assays. All animal experiments were approved by and conducted in 
accordance with St. Jude Children’s Research Hospital Animal Care and Use Committee 
guidelines.
Nucleic acid extraction
DNA and RNA were extracted from frozen tumors, tissues and cell lines using Trizol 
(Invitrogen, Carlsbad, CA, USA), and DNA from FFPE samples using a Qiagen DNeasy kit 
(Qiagen, Valencia, CA, USA), according to manufacturer’s instructions.
Identification of differentially methylated CpG sites
CpG sites showing significant differences between the SHH and other medulloblastoma 
subgroups (combined) were identified (Mann-Whitney U test, retaining probes significant 
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(p<0.05) after Benjamini-Hochberg false discovery rate (FDR) correction). All CpG sites 
identified showed an absolute change in average (mean) β≥0.34 between these groups. 
Differences in CpG methylation between the SHH subgroup and normal cerebella were 
assessed equivalently.
Analysis of DNA methylation status by bisulfite sequencing
Bisulfite DNA treatment was carried out using the Epitect bisulfite kit (Qiagen Ltd. 
Valencia, CA, USA), and PCR using standard reaction conditions (Supplementary Table 
S2). Purified products were directly sequenced with a CEQ DTCS kit (Beckman Coulter, 
High Wycombe, UK) and analyzed on a CEQ 2000XL DNA analysis system (Beckman 
Coulter). The methylation status at each CpG residue was determined by assessment of 
relative peak intensities, as previously described.12 The DNA methylation status 
(methylation score) of orthologous regions in the mouse and human genomes (mean, based 
on all sequenced CpG sites) was subsequently calculated for each region of interest.
cDNA synthesis and quantitative RT-PCR
cDNA was synthesized from total RNA using a Biorad iScript™ cDNA synthesis kit 
(Biorad, Irvine, CA, USA) according to manufacturer’s instructions. Measurements of VAV1 
transcript levels in mouse and human samples were determined using SYBR Green on the 
ABI PRISM 7900HT Detection System (Applied Biosystems, Foster City, CA, USA), using 
the comparative Ct relative quantification method (Supplementary Table S2).
RNA interference
Cells were seeded in 6- or 96-well plates and allowed to adhere for 24 hours, then 
transfected with 40nM small interfering RNA (siRNA) duplexes to VAV1 (sense strands: 
duplex1 CGUCGAGGUCAAGCACAUUdTdT;48 duplex2 
GCCAUCAGCAUUAAAUAUAdTdT, duplex3 UCAAAUACAAGGAGAGGUUdTdT 
(DharmaconGE, Layfayette, CO, USA) or negative control siRNA duplexes (sense 
UUCUCCGAACGUGUCACGUdTdT (Qiagen)) using Lipofectamine™ RNAiMAX 
(Invitrogen), following the manufacturer’s instructions.
Growth assays
Cells were seeded at 1 ×103 in 96-well plates and allowed to adhere for 24 hours. The 
number of viable cells at day 0 (prior to siRNA addition) and days 1-5 (after addition) was 
quantified using an XTT cell proliferation assay kit (Roche, Hertfordshire, UK) according to 
the manufacturer’s instructions. Experiments were performed in quadruplicate.
Flow cytometry
Adherent cells were harvested with trypsin 36 and 48 hours after siRNA transfection, fixed 
in ice-cold 70% ethanol/30% phosphate buffered saline (PBS) solution, then resuspended in 
40 mg/ml propidium iodide/0.1 mg/ml RNAse A (Sigma-Aldrich, Gillingham, UK) at 37°C 
for 30 minutes, and assessed using a FACScan (Becton Dickinson Oxford, UK) and Modfit 
software (Verity software, Maine, USA). Experiments were performed in quadruplicate.
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Retrovirus production
Plasmids used for retrovirus production were generated using the mouse stem cell virus LTR 
(MSCV) backbone expressing the green fluorescent protein (GFP) downstream of the 
internal ribosomal entry site (IRES) pMSCV-IRES-GFP. The full-length Vav1 cDNA 
(amino acids 1-845 (pMSCV-Vav1-IRES-GFP)) and the N-terminal region (amino acids 
1-186 (pMSCV-Vav1DN-IRES-GFP)) were inserted downstream of the MSCV LTR in the 
pMSCV-IRES-GFP plasmid. The pMSCV-Mycn-IRES-GFP construct and generation of 
retroviral stocks were previously described. 25
Mouse cerebellar and tumor cell purification, virus infection and orthotopic 
transplantations
GNP-enriched mouse cerebellar and medulloblastoma cells were purified by percoll 
gradient. 25, 49 Purified cells were plated on Matrigel-coated dishes and infected with 
retroviruses (GFP alone, Vav1-IRES-GFP, Vav1DN-IRES-GFP and Mycn-IRES-GFP). 2 
days after infection, cells were harvested, re-suspended in Matrigel (BD Biosciences, San 
Jose, CA, USA) and transplanted into CD-1 nu/nu mice (2.0 × 106 cells/injection) as 
previously described. 25 GNPs infected with GFP alone, Mycn-IRES-GFP or Vav1-IRES-
GFP retroviruses were transplanted into the cortices of recipient mice. Virally-infected 
tumor cells were transplanted in the flank of naïve recipient animals. Cortically-transplanted 
animals were sacrificed, when neurological symptoms were confirmed. Flank injections of 
virally-marked tumor cells were performed on both sides of each mouse; in the left side, 
2.0×106 tumor cells infected with GFP and on the other side, the same number of tumor 
cells infected with either Vav1/GFP or Vav1DN/GFP retroviruses. In parallel, a subset of 
infected cells was analyzed by FACS to calculate the efficiency of infection reflected by the 
percentage of GFP+ cells. Transplanted mouse recipients were monitored daily; tumors were 
harvested and weighed, and tumor cells purified by Percoll gradient and analyzed by FACS 
for GFP expression as previously described.3
Protein lysate preparation and immunoblotting
Whole-cell extracts were prepared from human cell lines, wild-type 1 month-old whole 
cerebella, Percoll-purified GNPs from P7 cerebella, and mouse Ptch+/− medulloblastomas. 
25-35 mg protein/sample was separated by gel electrophoresis and immunoblotted with 
defined antibodies as previously described.12 Primary antibodies were VAV1 (C14; Santa 
Cruz, Santa Cruz, CA, USA), Actin (Sigma-Aldrich) and HSC70 (K19; Santa Cruz). 
Appropriate secondary antibodies with horse radish peroxidise conjugates (Dakocymation 
Ltd, Glostrup, Denmark) were bound to the primary antibodies, followed by incubation with 
enhanced chemiluminescence (ECL or Dura) substrate (Pierce, Rockford, IL, USA), 
visualization by autoradiography, and densitometry using a Fuji-Las (Fujifilm Corporation, 
Tokyo, Japan) camera and the AIDA image analyzer program (Raytek, Sheffield, UK).
Ex-vivo cerebellar electroporation, organotypic slice culture and imaging
Plasmids for ex-vivo cerebellar slice experiments were generated using the pCIG2 vector, 
which contains a CAG promoter for high-level expression in CGNs and GNPs. The 
dominant-negative form of Vav1 (Vav1DN), the constitutively active form of Vav1 
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(Vav1CA) or H2B-mCherry cDNAs were inserted downstream of the CAG promoter in the 
pCIG2 expression vector.
Ex-vivo cerebellar electroporation and organotypic slice culture was performed on P7 mouse 
cerebella as described previously. 27 Migration distance measurements of fixed slices were 
performed by marking the centre of individual cell nuclei marked by mCherry-H2B using 
the pen function of SlideBook (Intelligent Imaging Innovations, Denver, CO, USA), 
exporting the cellular coordinates and calculating the distance between the center of each 
cell and the cerebellar surface using a custom written algorithm in Igor Pro (Wavemetrics 
Inc, Lake Oswego, OR, USA). All measurements were analyzed statistically using Microsoft 
Excel and graphed using Kaleidagraph v4.03 (Synergy software systems, Reading, PA, 
USA).
Statistical analysis
All array-based bioinformatic and statistical analyses were performed using R (v2.15.0)50 
and the stated statistical test. Survival analyses were performed using event-free survival 
(EFS) times. 15
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
Acknowledgements
This work was supported by grants from The Brain Tumour Charity (Grants 16/46 (S.C.C. and S.B) and 16/92 
(S.C.C., S.B., D.W. and J.L.)), NIH CA-096832, CA-02165-29 (M.F.R.), the American Lebanese Syrian Associated 
Charities of St. Jude Children’s Research Hospital (M.F.R., D.K.), the Mochida Foundation (D.K.), the Anderson 
fellowship (D.K.), LoveOliver (S.C.C. and D.W.) and Cancer Research UK (Grant C8464/A13457; S.C.C, S.B. and 
D.W.). Cell lines D425 Med and MEB-Med8A were gifts from Dr. D. Bigner (Duke University, Durham, USA) 
and Prof. T. Pietsch (University of Bonn Medical Centre, Bonn, Germany), respectively. Four normal cerebellar 
DNAs were gifts from Dr. M. Fruhwald (University of Munster, Munster, Germany). Vav1CA cDNA was a gift 
from Dr. S. Katzav (Hebrew University, Jerusalem, Israel). DAOY and D283 Med cell lines were from the ATCC 
(Manassas, USA). Approval from the Newcastle and North Tyneside Research Ethics Committee (study reference 
07/Q0905/71) was obtained for the collection, storage, and biological study of all material described. 
Medulloblastomas investigated in this study include samples provided by the UK Children’s Cancer and Leukaemia 
Group (CCLG) as part of CCLG-approved biological study BS-2007-04.
References
1. Pei Y, Moore CE, Wang J, Tewari AK, Eroshkin A, Cho YJ, et al. An animal model of MYC-driven 
medulloblastoma. Cancer cell. 2012; 21:155–67. [PubMed: 22340590] 
2. Taylor MD, Northcott PA, Korshunov A, Remke M, Cho YJ, Clifford SC, et al. Molecular 
subgroups of medulloblastoma: the current consensus. Acta neuropathologica. 2012; 123:465–72. 
[PubMed: 22134537] 
3. Kawauchi D, Robinson G, Uziel T, Gibson P, Rehg J, Gao C, et al. A mouse model of the most 
aggressive subgroup of human medulloblastoma. Cancer cell. 2012; 21:168–80. [PubMed: 
22340591] 
4. Gibson P, Tong Y, Robinson G, Thompson MC, Currle DS, Eden C, et al. Subtypes of 
medulloblastoma have distinct developmental origins. Nature. 2010; 468:1095–9. [PubMed: 
21150899] 
Lindsey et al. Page 12
Oncogene. Author manuscript; available in PMC 2016 March 03.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
5. Pizer BL, Clifford SC. The potential impact of tumour biology on improved clinical practice for 
medulloblastoma: progress towards biologically driven clinical trials. British journal of 
neurosurgery. 2009; 23:364–75. [PubMed: 19637007] 
6. Kool M, Jones DT, Jager N, Northcott PA, Pugh TJ, Hovestadt V, et al. Genome Sequencing of 
SHH Medulloblastoma Predicts Genotype-Related Response to Smoothened Inhibition. Cancer cell. 
2014; 25:393–405. [PubMed: 24651015] 
7. Ng JM, Curran T. The Hedgehog’s tale: developing strategies for targeting cancer. Nature reviews. 
2011; 11:493–501.
8. Rudin CM, Hann CL, Laterra J, Yauch RL, Callahan CA, Fu L, et al. Treatment of medulloblastoma 
with hedgehog pathway inhibitor GDC-0449. The New England journal of medicine. 2009; 
361:1173–8. [PubMed: 19726761] 
9. Kimura H, Ng JM, Curran T. Transient inhibition of the Hedgehog pathway in young mice causes 
permanent defects in bone structure. Cancer cell. 2008; 13:249–60. [PubMed: 18328428] 
10. Yauch RL, Dijkgraaf GJ, Alicke B, Januario T, Ahn CP, Holcomb T, et al. Smoothened mutation 
confers resistance to a Hedgehog pathway inhibitor in medulloblastoma. Science (New York, NY. 
2009; 326:572–4.
11. Northcott PA, Jones DT, Kool M, Robinson GW, Gilbertson RJ, Cho YJ, et al. Medulloblastomics: 
the end of the beginning. Nature reviews. 2012; 12:818–34.
12. Anderton JA, Lindsey JC, Lusher ME, Gilbertson RJ, Bailey S, Ellison DW, et al. Global analysis 
of the medulloblastoma epigenome identifies disease-subgroup-specific inactivation of COL1A2. 
Neuro Oncol. 2008; 10:981–94. [PubMed: 18664619] 
13. Northcott PA, Nakahara Y, Wu X, Feuk L, Ellison DW, Croul S, et al. Multiple recurrent genetic 
events converge on control of histone lysine methylation in medulloblastoma. Nat Genet. 2009; 
41:465–72. [PubMed: 19270706] 
14. Hovestadt V, Remke M, Kool M, Pietsch T, Northcott PA, Fischer R, et al. Robust molecular 
subgrouping and copy-number profiling of medulloblastoma from small amounts of archival 
tumour material using high-density DNA methylation arrays. Acta neuropathologica. 2013; 
125:913–6. [PubMed: 23670100] 
15. Schwalbe EC, Williamson D, Lindsey JC, Hamilton D, Ryan SL, Megahed H, et al. DNA 
methylation profiling of medulloblastoma allows robust subclassification and improved outcome 
prediction using formalin-fixed biopsies. Acta neuropathologica. 2013; 125:359–71. [PubMed: 
23291781] 
16. Uziel T, Zindy F, Xie S, Lee Y, Forget A, Magdaleno S, et al. The tumor suppressors Ink4c and 
p53 collaborate independently with Patched to suppress medulloblastoma formation. Genes & 
development. 2005; 19:2656–67. [PubMed: 16260494] 
17. Lee Y, Kawagoe R, Sasai K, Li Y, Russell HR, Curran T, et al. Loss of suppressor-of-fused 
function promotes tumorigenesis. Oncogene. 2007; 26:6442–7. [PubMed: 17452975] 
18. Hatton BA, Villavicencio EH, Tsuchiya KD, Pritchard JI, Ditzler S, Pullar B, et al. The Smo/Smo 
model: hedgehog-induced medulloblastoma with 90% incidence and leptomeningeal spread. 
Cancer Res. 2008; 68:1768–76. [PubMed: 18339857] 
19. Goodrich LV, Milenkovic L, Higgins KM, Scott MP. Altered neural cell fates and 
medulloblastoma in mouse patched mutants. Science (New York, NY. 1997; 277:1109–13.
20. Lusher ME, Lindsey JC, Latif F, Pearson AD, Ellison DW, Clifford SC. Biallelic epigenetic 
inactivation of the RASSF1A tumor suppressor gene in medulloblastoma development. Cancer 
Res. 2002; 62:5906–11. [PubMed: 12384556] 
21. Taylor RE, Bailey CC, Robinson K, Weston CL, Ellison D, Ironside J, et al. Results of a 
randomized study of preradiation chemotherapy versus radiotherapy alone for nonmetastatic 
medulloblastoma: The International Society of Paediatric Oncology/United Kingdom Children’s 
Cancer Study Group PNET-3 Study. J Clin Oncol. 2003; 21:1581–91. [PubMed: 12697884] 
22. Northcott PA, Shih DJ, Peacock J, Garzia L, Morrissy AS, Zichner T, et al. Subgroup-specific 
structural variation across 1,000 medulloblastoma genomes. Nature. 2012; 488:49–56. [PubMed: 
22832581] 
Lindsey et al. Page 13
Oncogene. Author manuscript; available in PMC 2016 March 03.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
23. Abe K, Whitehead IP, O’Bryan JP, Der CJ. Involvement of NH(2)-terminal sequences in the 
negative regulation of Vav signaling and transforming activity. J Biol Chem. 1999; 274:30410–8. 
[PubMed: 10521418] 
24. Fernandez-Zapico ME, Gonzalez-Paz NC, Weiss E, Savoy DN, Molina JR, Fonseca R, et al. 
Ectopic expression of VAV1 reveals an unexpected role in pancreatic cancer tumorigenesis. 
Cancer cell. 2005; 7:39–49. [PubMed: 15652748] 
25. Zindy F, Uziel T, Ayrault O, Calabrese C, Valentine M, Rehg JE, et al. Genetic alterations in 
mouse medulloblastomas and generation of tumors de novo from primary cerebellar granule 
neuron precursors. Cancer Res. 2007; 67:2676–84. [PubMed: 17363588] 
26. Hatten ME, Roussel MF. Development and cancer of the cerebellum. Trends in neurosciences. 
2011; 34:134–42. [PubMed: 21315459] 
27. Famulski JK, Trivedi N, Howell D, Yang Y, Tong Y, Gilbertson R, et al. Siah regulation of 
Pard3A controls neuronal cell adhesion during germinal zone exit. Science (New York, NY. 2010; 
330:1834–8.
28. Katzav S, Cleveland JL, Heslop HE, Pulido D. Loss of the amino-terminal helix-loop-helix domain 
of the vav proto-oncogene activates its transforming potential. Molecular and cellular biology. 
1991; 11:1912–20. [PubMed: 2005887] 
29. Lindsey JC, Schwalbe EC, Potluri S, Bailey S, Williamson D, Clifford SC. TERT promoter 
mutation and aberrant hypermethylation are associated with elevated expression in 
medulloblastoma and characterise the majority of non-infant SHH subgroup tumours. Acta 
neuropathologica. 2014; 127:307–9. [PubMed: 24337442] 
30. Remke M, Ramaswamy V, Peacock J, Shih DJ, Koelsche C, Northcott PA, et al. TERT promoter 
mutations are highly recurrent in SHH subgroup medulloblastoma. Acta neuropathologica. 2013; 
126:917–29. [PubMed: 24174164] 
31. Denkinger DJ, Borges CR, Butler CL, Cushman AM, Kawahara RS. Genomic organization and 
regulation of the vav proto-oncogene. Biochimica et biophysica acta. 2000; 1491:253–62. 
[PubMed: 10760587] 
32. Katzav S. Flesh and blood: the story of Vav1, a gene that signals in hematopoietic cells but can be 
transforming in human malignancies. Cancer Lett. 2007; 255:241–54. [PubMed: 17590270] 
33. Wu X, Northcott PA, Dubuc A, Dupuy AJ, Shih DJ, Witt H, et al. Clonal selection drives genetic 
divergence of metastatic medulloblastoma. Nature. 2012; 482:529–33. [PubMed: 22343890] 
34. Wechsler-Reya RJ, Scott MP. Control of neuronal precursor proliferation in the cerebellum by 
Sonic Hedgehog. Neuron. 1999; 22:103–14. [PubMed: 10027293] 
35. Hahn H, Wojnowski L, Specht K, Kappler R, Calzada-Wack J, Potter D, et al. Patched target Igf2 
is indispensable for the formation of medulloblastoma and rhabdomyosarcoma. J Biol Chem. 
2000; 275:28341–4. [PubMed: 10884376] 
36. Roussel MF, Hatten ME. Cerebellum development and medulloblastoma. Current topics in 
developmental biology. 2011; 94:235–82. [PubMed: 21295689] 
37. Quevedo C, Sauzeau V, Menacho-Marquez M, Castro-Castro A, Bustelo XR. Vav3-deficient mice 
exhibit a transient delay in cerebellar development. Molecular biology of the cell. 2010; 21:1125–
39. [PubMed: 20089829] 
38. Fischer KD, Kong YY, Nishina H, Tedford K, Marengere LE, Kozieradzki I, et al. Vav is a 
regulator of cytoskeletal reorganization mediated by the T-cell receptor. Curr Biol. 1998; 8:554–
62. [PubMed: 9601639] 
39. Sebban S, Farago M, Gashai D, Ilan L, Pikarsky E, Ben-Porath I, et al. Vav1 fine tunes p53 control 
of apoptosis versus proliferation in breast cancer. PloS one. 2013; 8:e54321. [PubMed: 23342133] 
40. Wells CM, Bhavsar PJ, Evans IR, Vigorito E, Turner M, Tybulewicz V, et al. Vav1 and Vav2 play 
different roles in macrophage migration and cytoskeletal organization. Experimental cell research. 
2005; 310:303–10. [PubMed: 16137676] 
41. Lazer G, Katzav S. Guanine nucleotide exchange factors for RhoGTPases: good therapeutic targets 
for cancer therapy? Cellular signalling. 2011; 23:969–79. [PubMed: 21044680] 
42. Oberley MJ, Wang DS, Yang DT. Vav1 in hematologic neoplasms, a mini review. American 
journal of blood research. 2012; 2:1–8. [PubMed: 22432082] 
Lindsey et al. Page 14
Oncogene. Author manuscript; available in PMC 2016 March 03.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
43. Ladd-Acosta C, Pevsner J, Sabunciyan S, Yolken RH, Webster MJ, Dinkins T, et al. DNA 
methylation signatures within the human brain. American journal of human genetics. 2007; 
81:1304–15. [PubMed: 17999367] 
44. Bibikova M, Lin Z, Zhou L, Chudin E, Garcia EW, Wu B, et al. High-throughput DNA 
methylation profiling using universal bead arrays. Genome research. 2006; 16:383–93. [PubMed: 
16449502] 
45. Schwalbe EC, Lindsey JC, Straughton D, Hogg TL, Cole M, Megahed H, et al. Rapid diagnosis of 
medulloblastoma molecular subgroups. Clin Cancer Res. 2011; 17:1883–94. [PubMed: 21325292] 
46. Ellison DW, Kocak M, Dalton J, Megahed H, Lusher ME, Ryan SL, et al. Definition of disease-
risk stratification groups in childhood medulloblastoma using combined clinical, pathologic, and 
molecular variables. J Clin Oncol. 2011; 29:1400–7. [PubMed: 20921458] 
47. Langdon JA, Lamont JM, Scott DK, Dyer S, Prebble E, Bown N, et al. Combined genome-wide 
allelotyping and copy number analysis identify frequent genetic losses without copy number 
reduction in medulloblastoma. Genes Chromosomes Cancer. 2006; 45:47–60. [PubMed: 
16149064] 
48. Bartolome RA, Molina-Ortiz I, Samaniego R, Sanchez-Mateos P, Bustelo XR, Teixido J. 
Activation of Vav/Rho GTPase signaling by CXCL12 controls membrane-type matrix 
metalloproteinase-dependent melanoma cell invasion. Cancer Res. 2006; 66:248–58. [PubMed: 
16397238] 
49. Zhao H, Ayrault O, Zindy F, Kim JH, Roussel MF. Post-transcriptional down-regulation of Atoh1/
Math1 by bone morphogenic proteins suppresses medulloblastoma development. Genes & 
development. 2008; 22:722–7. [PubMed: 18347090] 
50. RDevelopmentCoreTeam. In R Foundation for Statistical Computing. Vienna: 2011. R: a language 
and environment for statistical computing. 
Lindsey et al. Page 15
Oncogene. Author manuscript; available in PMC 2016 March 03.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
Figure 1. Identification of DNA methylation events associated with human MBSHH and their 
analysis in mouse tumors and cerebella identify VAV1/Vav1 hypo-methylation as a conserved 
cross-species epigenetic event in SHH-associated medulloblastomas
A. Heatmap showing the most differentially methylated CpG sites between human primary 
MBSHH tumors (n=50) and (i) non-MBSHH tumors (n=166) and (ii) cerebellar samples 
(n=21). Heatmap shows methylation scores (green (unmethylated) to red (fully-
methylated)). All CpG sites selected showed a statistically significant difference in average 
methylation status between groups (mean β difference >0.34 and adjusted p<0.05 following 
correction for multiple testing). B. and C. The DNA methylation status (methylation score) 
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of orthologous regions in the mouse and human genomes (mean, based on all CpG sites) 
was calculated for each gene of interest by bisulfite sequencing of 12 spontaneous 
medulloblastomas arising from four independent Shh-associated mouse models (genotypes 
indicated) and 11 strain-matched normal cerebella, in comparison with 6 MBSHH human 
tumors and 6 human cerebella. B. Heatmap shows methylation scores, from green 
(unmethylated) to red (fully-methylated) for individual mouse tumors and cerebella. ‘p’ 
indicates significance following Mann-Whitney tests. The difference between the average 
DNA methylation score for mouse cerebella, and the average methylation score for mouse 
tumor samples, is shown. C. Heatmap comparing average methylation scores in all analyzed 
tumors (T) and cerebella (C) from mice and humans. Conservation of overall methylation 
status between species (average methylation score difference ≤0.2) is indicated (Y, Yes; N, 
No).
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Figure 2. VAV1 hypo-methylation in MBSHH: Incidence, regional distribution, and association 
with clinical, pathological and molecular disease features
A. VAV1 methylation levels in our cohort of 216 primary medulloblastomas with subgroup 
classification. Box plots show methylation levels (β-value, probe E9) in the MBSHH 
subgroup (n=50) compared to non-MBSHH tumors (n=166) and normal cerebella (CB; 
n=21). The cerebellar methylation distribution (mean-3SD; cut-off marked) was used to 
distinguish hypo-methylated tumors (β<0.53) for subsequent assessment of clinical, 
pathological and molecular associations. ‘p’ value, Kruskal-Wallis test. non-MBSHH tumors 
are shown colored by subgroup (Group 3, yellow; WNT, blue; Group 4, green). B. 
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Methylation levels at adjacent CpG sites to probe E9, following analysis by bisulfite 
sequencing in representative MBSHH, non-MBSHH tumors and normal cerebella samples 
showing region-wide hypomethylation of CpG sites in the majority of MBSHH tumors. CpG 
sites are labelled by their position relative to the translational start site of VAV1. Black 
circles, ≥80% methylation; three-quarter black circles, ≥60%; half-black circles, ≥40%; 
quarter-black circles, ≥20% methylation; white circles, <20% methylation. C. Clinical, 
pathological and molecular features of VAV1 methylated and hypo-methylated tumors. ‘p’ 
values, X2 or Fisher’s exact test, as appropriate. D. Kaplan-Meier survival curves show 
event-free survival (EFS) for VAV1 hypo-methylated and methylated tumors (β-value, probe 
E9) in a sub-cohort of 36 primary MBSHH medulloblastomas comprising patients with 
available survival information, aged ≥3 and <16 years old at diagnosis, treated with standard 
upfront radiotherapy and chemotherapy 15. ‘p’ value, log-rank test.
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Figure 3. VAV1/Vav1 hypo-methylation is associated with elevated expression
A. RT-PCR analysis of VAV1 mRNA expression in human medulloblastoma cell lines 
before (−) and after (+) treatment with the DNA methyltransferase inhibitor, 5 AzaCdr. 
Mean VAV1 expression (+SE) is shown based on three independent replicates. B. DNA 
methylation levels at individual CpG sites in the assessed VAV1 region in human cell lines 
following analysis by bisulfite sequencing shown alongside the methylation score. Black 
circles, ≥80% methylation; three-quarter black circles, ≥60%; half-black circles, ≥40%; 
quarter-black circles, ≥20%; white circles, <20% methylation. C. RT-PCR analysis of Vav1 
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mRNA expression in Vav1 hypo-methylated mouse tumors (n=9; 3 each of Smo/Smo (blue 
circles), Ptch1+/− Cdkn2c−/− (light-blue squares) and Cdkn2c−/− p53FL/−, Nestin-Cre+ 
(grey-blue triangles) mice) and strain-matched Vav1 methylated normal mouse cerebella 
(CB; n=9; Smo/Smo matched strain, dark pink diamonds; Cdkn2c−/− strains, pink squares). 
D. RT-PCR analysis of VAV1 methylated (n=22) and hypo-methylated (n=12) human 
tumors and methylated human normal cerebella (CB; n=5). VAV1 methylation status was 
determined as described in Figure 2. E. VAV1 mRNA expression in a cohort of 255 primary 
human medulloblastomas previously described by 22 containing no WNT subgroup tumors. 
D and E. Molecular subgroup status is shown for human medulloblastomas (MBSHH, red; 
WNT, blue; Group 3, yellow; Group 4, green; non-classified, grey), and ‘p’ values (C, t-test; 
D, E, ANOVA) are indicated.
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Figure 4. VAV1 expression promotes proliferation in VAV1 hypo-methylated human 
medulloblastoma cells
A,B. Consistent reduction of VAV1 expression (60-70%) in VAV1 hypo-methylated DAOY 
medulloblastoma cells (Figure 3) at 3 days post-transfection with 3 anti-VAV1 siRNA 
duplexes, compared to non-silencing (NS) siRNA. A. Western blot shows representative 
VAV1 knockdown and graph shows the mean reduction in VAV1 expression (+SE; based 
on three independent replicates) caused by anti-VAV1 siRNA (duplex 1) relative to NS 
siRNA controls, following normalization to actin protein levels. B. RT-PCR analysis of 
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VAV1 mRNA expression at 3 days post-transfection with anti-VAV1 siRNA (duplexes 1-3). 
Graph shows mean reduction in VAV1 expression (+SE; based on four independent 
replicates) caused by VAV1 siRNA relative to NS siRNA controls, following normalization 
to the expression of a control gene (TBP). C. Cell proliferation following transfection with 
anti-VAV1 siRNA or NS siRNA, determined by XTT assay. Graphs show log2 number of 
cells at 1 to 5 days post-transfection relative to day 0 (before addition of siRNA). Results 
shown represent 4 independent replicates (+ SE). D. Fluorescence-activated cell sorting 
(FACS) analysis of cell cycle distribution at 3 days post-transfection (duplex 1). Graph 
shows mean (+SE) percentage of cells in each cell cycle phase, based on 4 independent 
replicates. Representative cell cycle distribution plots are shown for each siRNA. All ‘p’ 
values shown represent paired t-tests.
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Figure 5. Inhibition of SHH tumor maintenance by a dominant-negative form of Vav1
A-D. In each experiment Ptch1+/− Cdkn2c−/−mouse medulloblastoma cells infected with a 
GFP only virus were transplanted into the left side of recipient nude mice, whereas tumor 
cells infected with Vav1 or Vav1DN viruses were transplanted on the right side. Parallel 
FACS analysis revealed that approximately 20-40% tumor cells were infected. A. A 
representative mouse transplanted with tumor cells infected with GFP- (left) or Vav1DN/
GFP- (right) carrying retroviruses. A significantly larger tumor appeared on the left side 
from GFP alone-infected cells (white arrow). B. Surgically removed tumors from a mouse 
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in which tumors developed on both sides. Scale bar, 5mm. C. Quantification of the weight 
ratio between Vav1- or Vav1DN-expressing tumors compared to control GFP alone-
expressing tumors. *p<0.05. Black circles represent transplanted mice that did not develop 
tumors. D. Contribution of either Vav1-or Vav1DN-expressing cells to tumor maintenance. 
The GFP index is defined as the ratio of the percentage of GFP-positive tumor cells in the 
secondary tumors compared to the percentage of GFP-positive infected tumor cells before 
transplant. Note that 3 recipient mice did not develop secondary tumors from Vav1DN-
infected tumor cells (black triangles). *p<0.05. E. Kaplan-Meier survival curve of mice 
following stereotactic cortical transplantation of GNPs, infected with Vav1/GFP (n=8) or 
Mycn /GFP GNPs (n=7) retroviruses.
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Figure 6. Vav1 regulates GNP germinal zone exit and migration initiation in cerebellar 
development
A. Vav1 is expressed in purified P7 GNPs from wild-type (WT) mice and in Ptch1+/− 
tumors, relative to the normal cerebellum from one-month old mice. Western blot shows 
Vav1 and control protein (Hsc70) expression in independent samples. B E. P7 EGL was co-
electroporated with the indicated expression constructs and H2B-mCherry. After 24 (B, D) 
or 48 (C, E) hours of ex vivo culture, the migration distance of H2B-labeled CGN from the 
pial layer (outer dashed line) was analyzed. EGL boundary is between zero and 45 μm (first 
bin in histograms); red overlay indicates the average migration distribution of control cells at 
each time point. B. Most control cells remain within the EGL (dashed lines) at 24 h, while 
Vav1DN over-expressing cells have prematurely entered the ML and IGL. D. Migration 
distance versus frequency histogram of control neurons expressing only H2B-mCherry 
(n=967 cells) or Vav1DN over-expressing (n=2119 cells) CGNs. Control vs. Vav1DN, 
p=1.08×10−67 (Chi2 test). C. While control cells expressing only H2B-mCherry entered the 
ML and IGL after 48 h, Vav1CA over-expressing cells remained in the EGL. E. Migration 
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distance vs. frequency histogram of control (n=2252 cells) or Vav1CA over-expressing 
(n=2570 cells) CGNs. Control vs. Vav1CA, p= 0.0008 (Chi2 test). Scale bar, 100 μm.
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